Literature DB >> 19727615

Knowledge-based virtual screening: application to the MDM4/p53 protein-protein interaction.

Edgar Jacoby1, Andreas Boettcher, Lorenz M Mayr, Nathan Brown, Jeremy L Jenkins, Joerg Kallen, Caroline Engeloch, Ulrich Schopfer, Pascal Furet, Keiichi Masuya, Joanna Lisztwan.   

Abstract

Chemogenomics knowledge-based drug discovery approaches aim to extract the knowledge gained from one target and to apply it for the discovery of ligands and hopefully drugs of a new target which is related to the parent target by homology or conserved molecular recognition. Herein, we demonstrate the potential of knowledge-based virtual screening by applying it to the MDM4-p53 protein-protein interaction where the MDM2-p53 protein-protein interaction constitutes the parent reference system; both systems are potentially relevant to cancer therapy. We show that a combination of virtual screening methods, including homology based similarity searching, QSAR (Quantitative Structure-Activity Relationship) methods, HTD (High Throughput Docking), and UNITY pharmacophore searching provide a successful approach to the discovery of inhibitors. The virtual screening hit list is of the magnitude of 50,000 compounds picked from the corporate compound library of approximately 1.2 million compounds. Emphasis is placed on the facts that such campaigns are only feasible because of the now existing HTCP (High throughput Cherry-Picking) automation systems in combination with robust MTS (Medium Throughput Screening) fluorescence-based assays. Given that the MDM2-p53 system constitutes the reference system, it is not surprising that significantly more and stronger hits are found for this interaction compared to the MDM4-p53 system. Novel, selective and dual hits are discovered for both systems. A hit rate analysis will be provided compared to the full HTS (High-throughput Screening).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19727615     DOI: 10.1007/978-1-60761-274-2_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  5 in total

Review 1.  The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious.

Authors:  Grzegorz M Popowicz; Alexander Dömling; Tad A Holak
Journal:  Angew Chem Int Ed Engl       Date:  2011-02-21       Impact factor: 15.336

2.  Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists.

Authors:  Anna Czarna; Barbara Beck; Stuti Srivastava; Grzegorz M Popowicz; Siglinde Wolf; Yijun Huang; Michal Bista; Tad A Holak; Alexander Dömling
Journal:  Angew Chem Int Ed Engl       Date:  2010-07-19       Impact factor: 15.336

Review 3.  Targeting p53-MDM2-MDMX loop for cancer therapy.

Authors:  Qi Zhang; Shelya X Zeng; Hua Lu
Journal:  Subcell Biochem       Date:  2014

4.  Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists.

Authors:  David Koes; Kareem Khoury; Yijun Huang; Wei Wang; Michal Bista; Grzegorz M Popowicz; Siglinde Wolf; Tad A Holak; Alexander Dömling; Carlos J Camacho
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

Review 5.  Roles of computational modelling in understanding p53 structure, biology, and its therapeutic targeting.

Authors:  Yaw Sing Tan; Yasmina Mhoumadi; Chandra S Verma
Journal:  J Mol Cell Biol       Date:  2019-04-01       Impact factor: 6.216

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.